Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tyroserleutide in HCC After Resection
NCT03516448Phase 3Unknown
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
- Start
- Mar 2016
- Primary completion
- Jun 2016
- Modality
- Peptides, Small Molecules
01
Overview
A Phase 3 trial of tyroserleutide in hepatocellular carcinoma (HCC), sponsored by Shenzhen Kangzhe Pharmaceutical Co., Ltd.. Status: unknown.
02
Drugs
tyroserleutide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03516448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03516448.